Sign in

Trial result ·

Efficacy and Safety of Cuban Policosanol on Cognitive Function and Antioxidant Status in Adults with Subjective Memory Decline: A 12-Week Randomized, Double-Blinded, Placebo-Controlled Multicenter Trial.

Written based on 1 research study on PubMed, searched on 15 Nov 2026.

What was studied

This trial tested policosanol, a product made from Cuban sugarcane. It included adults aged 55 to 85 who felt their memory was slipping. People were put into groups by chance. Groups got a dummy pill, policosanol 20 mg, or policosanol 40 mg. Neither the people nor the staff knew who got what. Memory and thinking tests were done at the start and at 12 weeks. Blood tests were done at the same times. The key results came from a smaller set of 56 people.

What they found

In the 40 mg group, an antioxidant enzyme in the blood went up. The change in the dummy pill group was not clear. HDL cholesterol rose in both policosanol groups. It rose more with the higher dose. For HDL, both policosanol groups differed from the dummy pill group. Scores for place sense and language got better within both policosanol groups. But memory and thinking scores did not differ from the dummy pill group. The authors say people handled the product well.

What it means for patients

The authors say policosanol may raise HDL cholesterol, more so at a higher dose. They saw some gains in thinking within the policosanol groups. But these gains did not stand out against the dummy pill. They say more studies are needed to check these early results. Those studies would also look at effects on thinking and on HDL.

Why it is not certain yet

The trial lasted only 12 weeks. The key results came from a set of 56 people. This set left out people taking statins and people with some test scores. The authors call these results exploratory. Thinking gains were seen within groups, not when groups were compared. So the thinking results are not proven.

Source

Efficacy and Safety of Cuban Policosanol on Cognitive Function and Antioxidant Status in Adults with Subjective Memory Decline: A 12-Week Randomized, Double-Blinded, Placebo-Controlled Multicenter Trial.

PubMed · PMID 43030126

We restate facts from the source record in our own words. The original wording belongs to its publisher.

This page is not medical advice. Talk to your doctor about your own care.

Back to Mild cognitive impairment publications